• SPX
  • $5,893.62
  • 0.39 %
  • $23.00
  • DJI
  • $43,389.60
  • -0.13 %
  • -$55.39
  • N225
  • $38,429.37
  • 0.55 %
  • $208.52
  • FTSE
  • $8,109.32
  • 0.57 %
  • $45.71
  • IXIC
  • $18,791.81
  • 0.6 %
  • $111.69
MorphoSys AG (MOR) Stock Price, News & Analysis

MorphoSys AG (MOR) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$18.38
Day's range
$19.15
50-day range
$17.8
Day's range
$19.15
  • Country: DE
  • ISIN: US6177602025
52 wk range
$4.19
Day's range
$19.5
  • CEO: Dr. Jean-Paul Kress M.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.57
  • Piotroski Score 3.00
  • Grade Equal-Weight
  • Symbol (MOR)
  • Company MorphoSys AG
  • Price $18.96
  • Changes Percentage (2.43%)
  • Change $0.45
  • Day Low $18.38
  • Day High $19.15
  • Year High $19.50

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/29/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.50
  • Trailing P/E Ratio -11.97
  • Forward P/E Ratio -11.97
  • P/E Growth -11.97
  • Net Income $-189,734,199

Income Statement

Quarterly

Annual

Latest News of MOR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

MorphoSys AG Frequently Asked Questions

  • What is the MorphoSys AG stock price today?

    Today's price of MorphoSys AG is $18.96 — it has increased by +2.43% in the past 24 hours. Watch MorphoSys AG stock price performance more closely on the chart.

  • Does MorphoSys AG release reports?

    Yes, you can track MorphoSys AG's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the MorphoSys AG stock forecast?

    Watch the MorphoSys AG chart and read a more detailed MorphoSys AG stock forecast to see what analysts suggest you do with its shares.

  • What is MorphoSys AG stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by MorphoSys AG stock ticker.

  • How to buy MorphoSys AG stocks?

    Like other stocks, MOR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is MorphoSys AG's EBITDA?

    MorphoSys AG measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in MorphoSys AG’s financial statements.

  • What is the MorphoSys AG's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.7962713711, which equates to approximately -79.63%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in MorphoSys AG stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including MorphoSys AG's financials relevant news, and technical analysis. MorphoSys AG's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for MorphoSys AG stock currently indicates a “sell” signal. For more insights, review MorphoSys AG’s technical analysis.

  • A revenue figure for MorphoSys AG for its last quarter?

    MorphoSys AG published it's last quarterly revenues at $27.54 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.